Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pioglitazone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    193 result(s) found for: Pioglitazone. Displaying page 2 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-002237-20 Sponsor Protocol Number: ATS K021 Start Date*: 2006-08-21
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCA
    Medical condition: Type 2 diabetic patients treated with oral agents except PPAR gamma agonists and / or patients with insulin resistance measured by IRIS score > 50 with stable coronary artery disease and supposed e...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016678-34 Sponsor Protocol Number: CRO1456 Start Date*: 2010-04-15
    Sponsor Name:Imperial College London
    Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon
    Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004984-30 Sponsor Protocol Number: AD-4833/TOMM40_303 Start Date*: 2015-03-04
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Co...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003817-16 Sponsor Protocol Number: KIN001-202 Start Date*: 2019-04-04
    Sponsor Name:Kinarus AG
    Full Title: A 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care in patients wit...
    Medical condition: wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005931-56 Sponsor Protocol Number: 0431-064 Start Date*: 2007-02-06
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005263-97 Sponsor Protocol Number: CS0011-A-U302 Start Date*: 2008-02-28
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The study population is comprised of subjects with a prior diagnosis of type 2 diabetes who are either currently untreated (ie, not receiving antihyperglycemic medication within at least 2 months p...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004226-28 Sponsor Protocol Number: ATS K016 Start Date*: 2005-01-17
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications
    Medical condition: Type 2 Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004421-26 Sponsor Protocol Number: Leipzig-01 Start Date*: 2006-07-18
    Sponsor Name:Institut fuer Gesundheits- und Praxismanagement GmbH
    Full Title: Effect of Pioglitazone on Intima Media Thickness, Endothelial Function and Heart Rate Variability in Patients with Impaired Glucose Tolerance
    Medical condition: Impaired glucose tolerance
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003861-34 Sponsor Protocol Number: 0/2004 Start Date*: 2005-06-08
    Sponsor Name:Department of Nuclear Medicine
    Full Title: Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects
    Medical condition: There is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the de...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000186-11 Sponsor Protocol Number: Dresden-PPP-Trial Start Date*: 2006-09-22
    Sponsor Name:Med. Klinik / Kardiologie der Med. Fakultät Carl Gustav Carus an der Technischen Unversität Dresden
    Full Title: Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary...
    Medical condition: Male or female non-diabetic patients with coronary heart disease with AP or NSTEMI with indication for stent implantation and one additional coronary artery plaque (stenosis < 50%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003077-44 Sponsor Protocol Number: IT-PIO-109 Start Date*: 2008-02-28
    Sponsor Name:TAKEDA
    Full Title: EffectS of PiogLitazone on ENDOthelial progenitoR cells in type 2 diabetic patients with vascular complications - The SPLENDOR Study
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002354-30 Sponsor Protocol Number: ATS K019 / D-Pio-109 Start Date*: 2006-07-27
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic Control
    Medical condition: Diabetes Type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004296-35 Sponsor Protocol Number: RGHT000203 Start Date*: 2007-10-18
    Sponsor Name:The Royal Group of Hospitals, Belfast Health and Social Care Trust [...]
    1. The Royal Group of Hospitals, Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment
    Medical condition: The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment wit...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000421-39 Sponsor Protocol Number: AMLSG26-16/AML-ViVA Start Date*: 2017-02-03
    Sponsor Name:University Hospital Regensburg represented by Kaufmännischer Direktor
    Full Title: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myelo...
    Medical condition: acute myeloid leukemia refractory to standard induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003640-11 Sponsor Protocol Number: MK0431C-102 Start Date*: 2008-10-30
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Medical condition: Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed) AT (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005030-73 Sponsor Protocol Number: AVD111960 Start Date*: 2009-11-11
    Sponsor Name:GlaxoSmithKline
    Full Title: Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In Peopl...
    Medical condition: - Incidence of CV outcomes compared to placebo for the TZD class as a whole, rosiglitazone (RSG), and pioglitazone (PIO) when added to the therapeutic regimen of a person with type 2 diabetes who h...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) NL (Completed) DE (Completed) DK (Prematurely Ended) SK (Prematurely Ended) FR (Prematurely Ended) LV (Prematurely Ended) IE (Completed) IT (Prematurely Ended) FI (Completed) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005047-28 Sponsor Protocol Number: CS0011-A-U301 Start Date*: 2007-03-23
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The current study will support an indication for rivoglitazone as oral monotherapy to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with diet and exer...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LV (Completed) SK (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002790-38 Sponsor Protocol Number: 1603221 Start Date*: 2016-07-07
    Sponsor Name:Royal Devon & Exeter NHS Foundation Trust
    Full Title: TriMaster: Randomised Double-Blind Crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with type 2 diabetes who have suboptimal glycaemic co...
    Medical condition: Type 2 Diabetes Patients with type 2 diabetes who have suboptimal glycaemic control (HbA1c >58mmol/mol, 58%) on one or two oral therapies, not including a thiazolidinedione, a DPP4 inhibitor or a S...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-001218-42 Sponsor Protocol Number: 177/2004/U/Sper Start Date*: 2005-01-17
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis.
    Medical condition: Treatment of patients with gastric phlogosis (infected by Helicobacter pylori)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017904 Gastroenteritis helicobacter LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004467-65 Sponsor Protocol Number: DNTx Start Date*: 2007-04-24
    Sponsor Name:Technical University Dresden
    Full Title: Influence of pioglitazone for renal transplant function in diabetics
    Medical condition: nephropathy after renal transplantation in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 12:12:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA